Open AccessONCOLYTIC PARVOVIRUSES. A NEW APPROACHES FOR CANCER THERAPY
Author(s) -
В Б Локтев,
T. I. Ivan'kina,
Sergey V. Netesov,
П. М. Чумаков
Publication year - 2012
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn.v67i2.121
Subject(s) - oncolytic virus , parvovirus , cancer research , cancer , genetic enhancement , glioma , immunotoxin , biology , virology , parvoviridae , virus , gene , cytotoxicity , in vitro , genetics
Parvoviruses such as parvovirus H-1 (H-1PV) may selectively infect and lysis cancer cells. The parvoviruses also induce an immune system to eliminate the tumor cells through the formation of anti-cancer immunity. One of the possible mechanisms of antitumor activity is associated with the direct induction of apoptosis by parvoviral proteins NS1 and 11 kDa. Parvovirus-based vectors are promising for gene therapy of oncological diseases and genetic disorders in humans. Parvoviruses were successfully used for the experimental treatment on animal models of human glioma, neuroblastomas, lymphomas, pancreatic carcinoma, carcinomas and breast tumors. ParvOryx is the first oncolytic preparation constructed on the base of H-1PV; its phase I/IIa clinical trials in patients with glioblastoma multiforme are in process.